STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Clinical trials for STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double attack on devastating skin cancer
Disease control Recruiting nowThis study is testing a two-part treatment for a severe, widespread red rash caused by a rare skin cancer called cutaneous T-cell lymphoma (CTCL). It combines a drug (mogamulizumab) that targets cancer cells with a blood treatment (ECP) that aims to boost the immune system. The g…
Matched conditions: STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
When a rash might be a good sign: study probes skin lymphoma drug side effect
Knowledge-focused Recruiting nowThis study aims to better understand a common rash that occurs in patients with two types of skin lymphoma (mycosis fungoides and Sézary syndrome) who are taking the drug mogamulizumab. Researchers will observe 100 patients to learn how often this rash happens and to find ways to…
Matched conditions: STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC